Lower Serum Paraoxonase-1 Activity Is Related to Linoleic and Docosahexanoic Fatty Acids in Type 2 Diabetic Patients

Lewis, 2005, New insights into the regulation of HDL metabolism and reverse cholesterol transport, Circ Res, 96, 1221, 10.1161/01.RES.0000170946.56981.5c Oram, 2005, ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease, Physiol Rev, 85, 1343, 10.1152/physrev.00005.2005 Watson, 1995, Protective effect of high density lipoprotein associated paraoxonase-inhibition of the biological activity of minimally oxidised low-density lipoprotein, J Clin Invest, 96, 2882, 10.1172/JCI118359 Mackness, 2004, Paraoxonase 1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells, BBRC, 318, 680 Durrington, 2001, Paraoxonase and atherosclerosis, Arterioscler Thromb Vasc Biol, 21, 473, 10.1161/01.ATV.21.4.473 Chait, 2005, Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?, J Lipid Res, 46, 389, 10.1194/jlr.R400017-JLR200 Mackness, 2006, High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease, Atherosclerosis, 186, 396, 10.1016/j.atherosclerosis.2005.07.028 Dullaart, 2009, High plasma C-reactive protein (CRP) is related to low paraoxonase-1 (PON-1) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus, Clin Endocrinol, 70, 221, 10.1111/j.1365-2265.2008.03306.x Mackness, 2000, Low paraoxonase activity in type II diabetes complicated by retinopathy, Clin Sci, 98, 355, 10.1042/CS19990239 Mackness, 1997, Increased immunolocalisation of paraoxonase, clusterin and apolipoprotein AI in the human artery wall with progression of atherosclerosis, Arterioscler Thromb Vasc Biol, 17, 1233, 10.1161/01.ATV.17.7.1233 Aviram, 2000, Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxide-like activities, Circulation, 101, 2510, 10.1161/01.CIR.101.21.2510 Ferre, 2003, Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population, Clin Chem, 49, 1491, 10.1373/49.9.1491 Mackness, 1996, Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins, Curr Opin Lipidol, 7, 69, 10.1097/00041433-199604000-00004 Hegele, 1999, Paraoxonase genes and disease, Ann Med, 31, 217, 10.3109/07853899909115981 Mackness, 2000, Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits, Biochem Biophys Res Commun, 269, 232, 10.1006/bbrc.2000.2265 Sutherland, 1999, Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat, Arterioscler Thromb Vasc Biol, 19, 1340, 10.1161/01.ATV.19.5.1340 Van der Gaag, 1999, Daily moderate alcohol consumption increases serum paraoxonase activity: a diet-controlled, randomized intervention study in middle-aged men, Atherosclerosis, 147, 405, 10.1016/S0021-9150(99)00243-9 Hedrick, 2000, Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism, Arterioscler Thromb Vasc Biol, 20, 1946, 10.1161/01.ATV.20.8.1946 Brownlee, 2001, Biochemistry and molecular cell biology of diabetic complications, Nature, 414, 813, 10.1038/414813a Du, 2001, Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site, J Clin Invest, 108, 1341, 10.1172/JCI11235 Nishikawa, 2000, Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage, Nature, 404, 787, 10.1038/35008121 Pamplona, 2007, Highly resistant macromolecular components and low rate of generation of endogenous damage: two key traits of longevity, Ageing Res Rev, 6, 189, 10.1016/j.arr.2007.06.002 Kaneto, 2005, Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic β-cell dysfunction and insulin resistance, Int J Biochem Cell Biol, 37, 1595, 10.1016/j.biocel.2005.04.003 Haron, 1991, The aging: major risk factor for disease and death, Proc Natl Acad Sci USA, 88, 5360, 10.1073/pnas.88.12.5360 Brownlee, 2005, The pathobiology of diabetic complications: a unifying mechanism, Diabetes, 54, 1615, 10.2337/diabetes.54.6.1615 Ceradini, 2008, Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice, J Biol Chem, 283, 10930, 10.1074/jbc.M707451200 Pischon, 2003, Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among U.S. men and women, Circulation, 108, 155, 10.1161/01.CIR.0000079224.46084.C2 Rašić-Milutinović, 2007, Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients, Renal Failure, 29, 321, 10.1080/08860220601184092 Beauchamp, 1971, Superoxide dismutase: improved assays and an assay applicable to acrylamide gels, Anal Biochem, 44, 276, 10.1016/S0076-6879(84)05016-3 Stock, 1971, The autoxidation of human red cell lipids induced by hydrogen peroxide, Br J Haematol, 20, 95, 10.1016/0003-2697(71)90370-8 Salvati, 1981, Hemoglobinometry in human blood, Methods Enzymol, 76, 707, 10.1111/j.1365-2141.1971.tb00790.x Tamura, 1996, Mitochondrial targeting of GR requires a leader sequence, Biochem Biophys Res Commun, 222, 659, 10.1016/0076-6879(81)76152-4 Schiavon, 1996, Serum paraoxonase activity is decreased in uremic patients, Clin Chim Acta, 247, 71, 10.1006/bbrc.1996.0800 Folch, 1957, A simple method for the isolation and purification of total lipids from animal tissues, J Biol Chem, 497, 10.1016/0009-8981(95)06221-1 Aebi, 1984, Catalase in vitro, Methods Enzymol, 105, 121, 10.1016/S0076-6879(84)05016-3 Kabaroglu, 2004, Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes, Acta Cardiol, 59, 606, 10.2143/AC.59.6.2005242 Costa, 2005, Modulation of paraoxonase (PON1) activity, Biochem Pharmacol, 69, 541, 10.1016/j.bcp.2004.08.027 Camps, 2009, The paraoxonases: role in human diseases and methodological difficulties in measurement, Crit Rev Clin Lab Sci, 46, 83, 10.1080/10408360802610878 Lawlor, 2004, The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women’s Heart and Health Cohort Study and a meta-analysis, BMC Genet, 5, 17, 10.1186/1471-2156-5-17 Bhattacharyya, 2008, Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk, JAMA, 299, 1265, 10.1001/jama.299.11.1265 Senti, 2003, Antioxidant paraoxonase 1 activity in the metabolic syndrome, J Clin Endocrinol Metab, 88, 5422, 10.1210/jc.2003-030648 Babiy, 1992, Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation, Biochem Pharmacol, 43, 995, 10.1016/0006-2952(92)90604-H Hedrick, 2000, Glycation impairs high-density lipoprotein function, Diabetologia, 43, 312, 10.1007/s001250050049 Aviram, 1999, Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants, Free Radic Biol Med, 26, 892, 10.1016/S0891-5849(98)00272-X Mackness, 2003, Low paraoxonase activity predicts coronary events in the Caerphilly prospective study, Circulation, 107, 2775, 10.1161/01.CIR.0000070954.00271.13 Feingold, 1998, Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response, Atherosclerosis, 139, 307, 10.1016/S0021-9150(98)00084-7 Deakin, 2007, HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity, Arterioscler Thromb Vasc Biol, 27, 1146, 10.1161/ATVBAHA.107.141747 Kappelle, 2011, Lower serum paraoxonase-1 activity is related to higher serum amyloid A levels in metabolic syndrome, Arch Med Res, 42, 219, 10.1016/j.arcmed.2011.05.002 Senti, 2001, Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase1 gene: the REGICOR study, Atherosclerosis, 156, 443, 10.1016/S0021-9150(00)00680-8 Ahmed, 2005, Advanced glycation endproducts—role in pathology of diabetic complications, Diabetes Res Clin Pract, 67, 3, 10.1016/j.diabres.2004.09.004 Fried, 1998, Omental and subcutaneous adipose tissue of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid, J Clin Endocrinol Metab, 83, 847, 10.1210/jc.83.3.847 Bastard, 2000, Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss, J Clin Endocrinol Metab, 85, 3338, 10.1210/jc.85.9.3338 Anty, 2006, The inflammatory C-reactive protein is increased in both liver, and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH, Am J Gastroenterol, 101, 1824, 10.1111/j.1572-0241.2006.00724.x Ridker, 2000, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N Engl J Med, 342, 836, 10.1056/NEJM200003233421202 Tice, 2003, The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women, Am J Med, 114, 199 Khan, 2003, Role of nuclear receptors in the regulation of gene expression by dietary fatty acids, J Nutr Biochem, 14, 554, 10.1016/S0955-2863(03)00098-6 Marx, 1999, PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells, Circulation, 99, 3125, 10.1161/01.CIR.99.24.3125 Ricote, 2004, Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis, Arterioscler Thromb Vasc Biol, 24, 230, 10.1161/01.ATV.0000103951.67680.B1 Bagga, 2003, Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion, Proc Natl Acad Sci USA, 100, 1751, 10.1073/pnas.0334211100 González-Périz, 2009, Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins, FASEB J, 23, 1946, 10.1096/fj.08-125674 Pan, 1995, Skeletal muscle membrane lipid composition is related to adiposity and insulin action, J Clin Invest, 96, 2802, 10.1172/JCI118350 Oh, 2010, GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects, Cell, 142, 687, 10.1016/j.cell.2010.07.041 Calder, 2007, Immunomodulation by omega-3 fatty acids, Prostaglandins Leukot Essent Fatty Acids, 77, 327, 10.1016/j.plefa.2007.10.015 Baguley, 2004, Understanding statistical power in the context of applied research, Appl Ergonom, 35, 73, 10.1016/j.apergo.2004.01.002